Trial Outcomes & Findings for Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (NCT NCT05028582)

NCT ID: NCT05028582

Last Updated: 2025-07-17

Results Overview

The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 432 participants
• Primary outcome timeframe: Week 8
• Results posted on: 2025-07-17

Participant Flow

Participants were enrolled at 53 study centers in the US and Canada.

Participant milestones

Measure	Roflumilast Foam 0.3% Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Overall Study STARTED	281	151
Overall Study COMPLETED	250	126
Overall Study NOT COMPLETED	31	25

Reasons for withdrawal

Measure	Roflumilast Foam 0.3% Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Overall Study Lost to Follow-up	11	9
Overall Study Withdrawal by Subject	9	10
Overall Study Adverse Event	5	2
Overall Study Miscellaneous	3	2
Overall Study Lack of Efficacy	3	1
Overall Study Physician Decision	0	1

Baseline Characteristics

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Baseline characteristics by cohort

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.	Total n=432 Participants Total of all reporting groups
Age, Continuous	48.6 years STANDARD_DEVIATION 14.93 • n=5 Participants	45.0 years STANDARD_DEVIATION 14.33 • n=7 Participants	47.3 years STANDARD_DEVIATION 14.81 • n=5 Participants
Sex: Female, Male Female	152 Participants n=5 Participants	91 Participants n=7 Participants	243 Participants n=5 Participants
Sex: Female, Male Male	129 Participants n=5 Participants	60 Participants n=7 Participants	189 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	48 Participants n=5 Participants	28 Participants n=7 Participants	76 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	224 Participants n=5 Participants	121 Participants n=7 Participants	345 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	9 Participants n=5 Participants	2 Participants n=7 Participants	11 Participants n=5 Participants
Race/Ethnicity, Customized American-Indian or Alaska Native	0 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants
Race/Ethnicity, Customized Asian	26 Participants n=5 Participants	4 Participants n=7 Participants	30 Participants n=5 Participants
Race/Ethnicity, Customized Black or African-American	12 Participants n=5 Participants	6 Participants n=7 Participants	18 Participants n=5 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	3 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants
Race/Ethnicity, Customized White	225 Participants n=5 Participants	129 Participants n=7 Participants	354 Participants n=5 Participants
Race/Ethnicity, Customized Other	11 Participants n=5 Participants	7 Participants n=7 Participants	18 Participants n=5 Participants
Race/Ethnicity, Customized More than One Race	4 Participants n=5 Participants	1 Participants n=7 Participants	5 Participants n=5 Participants

PRIMARY outcome

Timeframe: Week 8

Population: All randomized participants are included, with multiple imputation of missing data.

The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8	66.4 percentage of participants Interval 59.62 to 72.56	27.8 percentage of participants Interval 20.12 to 37.1

PRIMARY outcome

Timeframe: Week 8

Population: All randomized participants are included, with multiple imputation of missing data.

The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8	45.5 percentage of participants Interval 38.87 to 52.33	20.1 percentage of participants Interval 13.55 to 28.81

SECONDARY outcome

Timeframe: Week 2

Population: All randomized participants with weekly average baseline SI-NRS ≥4 are included.

The percentage of participants with SI-NRS success at Week 2 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=203 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=123 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2	25.2 percentage of participants Interval 18.96 to 32.63	8.0 percentage of participants Interval 3.9 to 15.55

SECONDARY outcome

Timeframe: Week 4

Population: All randomized participants with weekly average baseline SI-NRS ≥4 are included.

The percentage of participants with SI-NRS success at Week 4 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=203 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=123 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of SI-NRS Success at Week 4	46.2 percentage of participants Interval 38.32 to 54.22	16.8 percentage of participants Interval 10.4 to 26.04

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants with weekly average baseline SI-NRS ≥4 are included.

The percentage of participants with SI-NRS success at Week 8 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=203 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=123 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of SI-NRS Success at Week 8	65.3 percentage of participants Interval 57.26 to 72.58	30.3 percentage of participants Interval 21.38 to 40.91

SECONDARY outcome

Timeframe: Day 1

Population: All randomized participants with average, weekly SI-NRS ≥4 at baseline are included.

SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Change From Baseline in SI-NRS Score at Day 1	-0.44 score on a scale Standard Error 0.120	-0.09 score on a scale Standard Error 0.149

SECONDARY outcome

Timeframe: Day 3

Population: All randomized participants are included.

SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Change From Baseline in SI-NRS Score at Day 3	-1.11 score on a scale Standard Error 0.133	-0.36 score on a scale Standard Error 0.165

SECONDARY outcome

Timeframe: Week 1

Population: All randomized participants are included.

SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Change From Baseline in SI-NRS Score at Week 1	-1.08 score on a scale Standard Error 0.121	-0.53 score on a scale Standard Error 0.151

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants with average, weekly WI-NRS ≥4 at baseline are included.

WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from 0 ("no itch") to 10 ("worst imaginable itch"). Success is defined as achievement of a ≥ 4-point improvement from baseline in participants with a baseline WI-NRS pruritus score of ≥ 4.

Outcome measures

Measure	Roflumilast Foam 0.3% n=203 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=110 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8	63.1 percentage of participants Interval 54.97 to 70.59	30.1 percentage of participants Interval 20.69 to 41.44

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants are included, with multitple imputation of missing data.

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)	50.1 percentage of participants Interval 43.24 to 56.91	16.8 percentage of participants Interval 10.77 to 25.15

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants ≥18 years of age are included.

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The aggregate Itching, Pain, and Scaling score ranges from 0 to 30; the change from baseline in aggregate score was assessed per protocol only in adult participants.

Outcome measures

Measure	Roflumilast Foam 0.3% n=274 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=148 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)	-10.87 score on a scale Standard Error 0.546	-5.75 score on a scale Standard Error 0.698

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants ≥18 years of age are included.

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.

Outcome measures

Measure	Roflumilast Foam 0.3% n=274 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=148 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8	31.7 percentage of participants Interval 25.63 to 38.58	10.0 percentage of participants Interval 5.55 to 17.32

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants ≥18 years of age are included.

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Pain score ranges from 0 to 10.

Outcome measures

Measure	Roflumilast Foam 0.3% n=274 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=148 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8	64.9 percentage of participants Interval 58.03 to 71.24	40.3 percentage of participants Interval 31.36 to 49.95

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants ≥18 years of age are included.

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.

Outcome measures

Measure	Roflumilast Foam 0.3% n=274 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=148 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8	41.5 percentage of participants Interval 34.86 to 48.54	13.6 percentage of participants Interval 8.26 to 21.59

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants ≥18 years of age are included.

Outcome measures

Measure	Roflumilast Foam 0.3% n=274 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=148 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Percentage of Participants Achieving PSD Total Score of 0 at Week 8	19.6 percentage of participants Interval 14.65 to 25.82	7.1 percentage of participants Interval 3.5 to 13.79

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants are included, with multiple imputation of missing data..

The PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)	70.9 percentage of participants Interval 64.27 to 76.7	31.3 percentage of participants Interval 23.15 to 40.72

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants are included, with multiple imputation of missing data.

The percentage of participants with S-IGA score of 0 Week 8 is presented. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of S-IGA Score of 'Clear' at Week 8	40.0 percentage of participants Interval 33.47 to 46.81	9.1 percentage of participants Interval 4.88 to 16.18

SECONDARY outcome

Timeframe: Week 2

Population: All randomized participants are included, with multiple imputation of missing data.

The percentage of participants with S-IGA success at Week 2 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of S-IGA Success at Week 2	30.4 percentage of participants Interval 24.62 to 36.92	11.7 percentage of participants Interval 6.9 to 19.2

SECONDARY outcome

Timeframe: Week 4

Population: All randomized participants are included, with multiple imputation of missing data.

The percentage of participants with S-IGA success at Week 4 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Achievement of S-IGA Success at Week 4	53.8 percentage of participants Interval 47.0 to 60.46	19.5 percentage of participants Interval 13.09 to 27.95

SECONDARY outcome

Timeframe: Week 2

Population: All randomized participants are included, with multiple imputation of missing data.

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.

Outcome measures

Measure	Roflumilast Foam 0.3% n=281 Participants Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 Participants Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Change From Baseline in PASI Score at Week 2	-2.31 score on a scale Standard Error 0.157	-1.03 score on a scale Standard Error 0.193

Adverse Events

Roflumilast Foam 0.3%

Serious events: 2 serious events

Other events: 0 other events

Deaths: 0 deaths

Vehicle Foam

Serious events: 1 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	Roflumilast Foam 0.3% n=281 participants at risk Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% qd for 8 weeks.	Vehicle Foam n=151 participants at risk Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Psychiatric disorders Bipolar disorder	0.36% 1/281 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.	0.00% 0/151 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.
Gastrointestinal disorders Gastritis	0.36% 1/281 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.	0.00% 0/151 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/281 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.	0.66% 1/151 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.
Injury, poisoning and procedural complications Joint dislocation	0.00% 0/281 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.	0.66% 1/151 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.
Vascular disorders Peripheral artery occlusion	0.00% 0/281 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.	0.66% 1/151 • Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up) All treated participants are included.

Other adverse events

Adverse event data not reported

Additional Information

Arcutis Medical Information

Arcutis Biotherapeutics

Phone: +1 (844) 692-6729

Email: medinfo@arcutis.com

Results disclosure agreements

• Principal investigator is a sponsor employee The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.
• Publication restrictions are in place

Restriction type: OTHER